The first drug of a new antibiotic class has been approved for urinary tract infections and gonorrhoea, offering a fresh weapon against drug-resistant bacteria. Gepotidacin, sold as Blujepa by GSK, is a first-in-class triazaacenaphthylene antibiotic that blocks two bacterial enzymes, DNA gyrase and topoisomerase IV, which bacteria need to copy their DNA. The US Food and Drug Administration approved it for uncomplicated urinary tract infections in females aged 12 and over who weigh at least 40 kilograms, and in December 2025 for uncomplicated urogenital gonorrhoea in patients aged 12 and over weighing at least 45 kilograms who have limited or no alternative treatments. It is also approved in Britain. In the EAGLE-2 and EAGLE-3 trials it was non-inferior to nitrofurantoin for urinary infections and superior in EAGLE-3, while in the EAGLE-1 trial it matched ceftriaxone plus azithromycin for gonorrhoea. The most common side effects were diarrhoea, nausea and stomach pain.
What the Evidence Shows
New antibiotics are desperately needed because resistance is rising. A landmark study estimated that drug-resistant bacterial infections directly caused 1.27 million deaths worldwide in 2019, and gonorrhoea in particular is becoming harder to treat as strains resist more drugs. Gepotidacin works through a mechanism distinct from existing antibiotic classes, which is why it can kill bacteria that resist older drugs. But it is expensive and carries warnings, including a risk of heart rhythm changes and Clostridioides difficile infection, so experts say it should be reserved for patients without other options. Guidelines still recommend nitrofurantoin, trimethoprim-sulfamethoxazole or fosfomycin as first-line treatment for urinary infections. Careful stewardship will decide whether the new drug stays useful or follows older antibiotics into resistance. The drug is taken as tablets twice a day for five days for urinary infections, and doctors must weigh its benefits against the warnings on the label. Reporting and analysis from sources such as The Lancet track the same developments, and specialists following gepotidacin, the new antibiotic say the direction is now consistent across independent lines of evidence.
The Wider Context
Equity runs through every discussion of gepotidacin, the new antibiotic. Interventions that require apps, fees or free weekday afternoons reliably reach the people who need them least, so the programmes earning praise are those designed around clinics, workplaces and community venues that already serve everyone. Evaluation reports now publish uptake by income and region as a matter of routine.
What Happens Next
The practical takeaway on gepotidacin, the new antibiotic is deliberately unglamorous: it works best as part of ordinary, well-delivered care rather than as a standalone fix. Health services are planning on that basis, building the referral routes and follow-up that turn a promising result into population benefit. The gains arrive slowly and then, in the statistics, unmistakably. You can follow related developments in our coverage of health.
It is also worth remembering how quickly the picture in this area has changed before. Positions that looked settled a few years ago have been revised as new data arrived, and the same humility is appropriate now. The strongest coverage of this subject, and the most useful advice, tends to come from sources that update their views openly when the facts move, rather than defending an earlier position long after it has stopped fitting the evidence available.

